Table 1A

Demographics, clinical characteristics and potential factors associated with the choice of treatment by treatment group

ChoiceASRP/RTAll
n451 (100.0)837 (100.0)1288 (100.0)
Age, n (range)64 (61–67)62 (58–65)63 (59–66)
Marital status n (%)
 Married or domestic partner367 (81.4)701 (83.8)1068 (82.9)
 Other73 (16.2)126 (15.1)199 (15.5)
 Missing11 (2.4)10 (1.2)21 (1.6)
Children n (%)
 No children36 (8.0)70 (8.4)106 (8.2)
 Children401 (88.9)747 (89.2)1148 (89.1)
 Missing14 (3.1)20 (2.4)34 (2.6)
Work status, n (%)
 Not retired74 (16.4)211 (25.2)285 (22.1)
 Retired377 (83.6)626 (74.8)1003 (77.9)
 Missing0 (0.0)0 (0.0)0 (0.0)
Education level, n (%)
 Compulsory school143 (31.7)208 (24.9)351 (27.3)
 Secondary school166 (36.8)347 (41.5)513 (39.8)
 University128 (28.4)265 (31.7)393 (30.5)
 Missing14 (3.1)17 (2.0)31 (2.4)
Charlson Comorbidity Index, n (%)
 0129 (28.6)282 (33.7)411 (31.9)
 1142 (31.5)296 (35.4)438 (34.0)
 285 (18.8)144 (17.2)229 (17.8)
 >295 (21.1)115 (13.7)210 (16.3)
Psychiatric illness, n (%)
 No411 (91.1)770 (92.0)1181 (91.7)
 Yes (depression/other)40 (8.9)67 (8.0)107 (8.3)
T-stage
 T1ab37 (8.2)16 (1.9)53 (4.1)
 T1c354 (78.5)599 (71.6)953 (74.0)
 T260 (13.3)222 (26.5)282 (21.9)
PSA value at diagnosis, n (%)
 0–3.031 (6.9)41 (4.9)72 (5.6)
 3.1–7.0325 (72.1)597 (71.3)922 (71.6)
 7.1–10.095 (21.1)199 (23.8)294 (22.8)
Method of detection n (%)
 Screening228 (50.6)481 (57.5)709 (55.0)
 LUTS162 (5.7)216 (25.8)377 (29.3)
 Other symptoms51 (11.3)109 (13.0)160 (12.4)
 Missing11 (2.4)31 (3.7)42 (3.3)
Alone when being notified of the cancer diagnosis n (%) 
 No107 (23.7)256 (30.6)363 (28.2)
 Yes332 (73.6)568 (67.9)900 (69.9)
 Missing12 (2.7)13 (1.6)25 (1.9)
Sufficient time from diagnosis until treatment decision, n (%)
 No, i wanted a quicker decision27 (6.0)48 (5.7)75 (5.8)
 Yes363 (80.5)739 (88.3)1102 (85.6)
 No, i wanted more time to think11 (2.4)35 (4.2)46 (3.6)
 Missing50 (11.1)15 (1.8)65 (5.0)
  • AS, active surveillance; LUTS, lower urinary tract symptoms; PSA, prostate-specific antigen; RP/RT, radical prostatectomy or radiotherapy.